Federal Court Upholds Medicare Drug Price Negotiation Program, Rejects Merck's Challenge
Merck & Co., Inc. (NYSE:MRK) has seen its challenge to the Medicare Drug Price Negotiation Program rejected by a federal court.
The program, part of the Inflation Reduction Act, allows the government to negotiate maximum fair prices for certain high-expenditure drugs with no generic competitors and more than seven years of regulatory approval.
Under the guidelines, the lowest maximum fair price is sought for each chosen drug, capping negotiations at 75% of private market value. Participating drugmakers must agree to official prices that guarantee Medicare beneficiaries access until generic alternatives enter the market.
Pharmaceutical companies that decline participation or fail to reach pricing agreements face escalating excise taxes on all product sales, including non-Medicare transactions. Penalties start at 185.71% of the drug's sales price and can escalate up to 1,900% after 270 days.